DIFICLIR significantly reduces recurrence and mortality when used first-line in patients with CDI

Data presented from the CDI Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes. Compared to traditional broad-spectrum antibiotics, first-line use of fidaxomicin, a targeted treatment, in all CDI patients provides improved outcomes in terms of recurrence rate, all-cause mortality and cost effectiveness, compared to use in selected patients only. (8) CDI is associated with high-mortality (5,6,7) and cost burden, (9) therefore reducing the incidence and recurrence of CDI is a priority for clinicians, payers and health authorities alike.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Association News Practical therapeutics Cost effectiveness Industry News Infectious Disease broad-spectrum antibiotics cdi DIFICLIR fidaxomicin Latest News Source Type: news